FDA approves dupilumab for severe eczema

Nature Reviews Drug Discovery 16, 305 (2017). doi:10.1038/nrd.2017.90 Author: Asher Mullard The FDA approved Regeneron and Sanofi's first-in-class candidate dupilumab for the treatment of moderate-to-severe eczema.T helper 2 type responses have emerged as a unifying feature of various inflammatory and allergic diseases, such as eczema and asthma. As a result, type 2 cytokines —
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research